Evidence map›Paper›PMID 24768688›Full record

ArticleJournal of biotechnology2014

A new insect cell glycoengineering approach provides baculovirus-inducible glycogene expression and increases human-type glycosylation efficiency.

Ann M Toth, Chu-Wei Kuo, Kay-Hooi Khoo, Donald L Jarvis

Open access · greenAbstract read
In one paragraph

Article in Journal of biotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Impact of Protein Glycosylation on the Design of Viral Vaccines.Advances in biochemical engineering/biotechnology · 2021
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Ann M TothDepartment of Molecular Biology, University of Wyoming, Laramie, WY 82071, USA.
Chu-Wei KuoInstitute of Biological Chemistry, Academia Sinica, Nankang, Taipei 115, Taiwan.
Kay-Hooi KhooInstitute of Biological Chemistry, Academia Sinica, Nankang, Taipei 115, Taiwan.
Donald L JarvisDepartment of Molecular Biology, University of Wyoming, Laramie, WY 82071, USA. Electronic address: dljarvis@uwyo.edu.
Institute of Biological Chemistry, Academia Sinica · TWUniversity of Wyoming · US

Funding

N-GLYCOSYLATION MECHANISM IN INSECT CELLSR01GM049734 · NIGMS · UNIVERSITY OF WYOMING · PI JARVIS, DONALD L. · 1994 to 2010
$2.7M
Glycoengineered insect cells for commercial biologics manufacturingR44GM102982 · NIGMS · GLYCOBAC, LLC · PI BLAIR, CAROL D, JARVIS, DONALD L. · 2016 to 2017
$940k
Glycoengineering insect cells for commercial recombinant glycoprotein productionR43GM102982 · NIGMS · GLYCOBAC, LLC · PI GEISLER, CHRISTOPH, JARVIS, DONALD L. · 2013 to 2014
$599k
NIGMS NIH HHS GM102982NIGMS NIH HHS GM49734NIGMS NIH HHS R01 GM049734NIGMS NIH HHS R43 GM102982NIGMS NIH HHS R44 GM102982
6 · The paper itself

Abstract

Insect cells are often glycoengineered using DNA constructs encoding foreign glyocoenzymes under the transcriptional control of the baculovirus immediate early promoter, ie1. However, we recently found that the delayed early baculovirus promoter, 39K, provides inducible and higher levels of transgene expression than ie1 after baculovirus infection (Lin and Jarvis, 2013). Thus, the purpose of this study was to assess the utility of the 39K promoter for insect cell glycoengineering. We produced two polyclonal transgenic insect cell populations in parallel using DNA constructs encoding foreign glycoenzymes under either ie1 (Sfie1SWT) or 39K (Sf39KSWT) promoter control. The surface of Sfie1SWT cells was constitutively sialylated, whereas the Sf39KSWT cell surface was only strongly sialylated after baculovirus infection, indicating Sf39KSWT cells were inducibly-glycoengineered. All nine glycogene-related transcript levels were induced by baculovirus infection of Sf39KSWT cells and most reached higher levels in Sf39KSWT than in Sfie1SWT cells at early times after infection. Similarly, galactosyltransferase activity, sialyltransferase activity, and sialic acid levels were induced and reached higher levels in baculovirus-infected Sf39KSWT cells. Finally, two different recombinant glycoproteins produced by baculovirus-infected Sf39KSWT cells had lower proportions of paucimannose-type and higher proportions of sialylated, complex-type N-glycans than those produced by baculovirus-infected Sfie1SWT cells. Thus, the 39K promoter provides baculovirus-inducible expression of foreign glycogenes, higher glycoenzyme activity levels, and higher human-type N-glycan processing efficiencies than the ie1 promoter, indicating that this delayed early baculovirus promoter has great utility for insect cell glycoengineering.

Indexed as

AnimalsBaculoviridaeCell LineCell ProliferationErythropoietinGlycoproteinsHumansN-Acetylneuraminic AcidProtein EngineeringRecombinant ProteinsSpodopteraTransgenesErythropoietinGlycoproteinsN-Acetylneuraminic AcidRecombinant ProteinsBaculovirus expression vector systemBaculovirus promotersGlycoengineeringInsect cell glycosylation

Identifiers

PMID24768688
PMCPMC4095979
OpenAlexW2005931422

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.